Peter Rieckmann Selected Research

Cladribine

1/2021	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.
1/2021	Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.
11/2020	Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion.
6/2020	Cladribine Tablets and Relapsing-Remitting Multiple Sclerosis: A Pragmatic, Narrative Review of What Physicians Need to Know.
1/2020	Expert opinion on the use of cladribine tablets in clinical practice.
4/2019	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis.
1/2019	Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
1/2019	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study.
10/2018	Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
4/2013	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Peter Rieckmann Research Topics

Disease

48	Multiple Sclerosis 08/2022 - 03/2002
17	Relapsing-Remitting Multiple Sclerosis 06/2020 - 01/2004
4	Inflammation (Inflammations) 01/2016 - 12/2002
3	Infections 01/2020 - 04/2003
3	Disease Progression 09/2011 - 11/2008
2	Neoplasms (Cancer) 01/2020 - 01/2006
2	Lymphopenia (Lymphocytopenia) 10/2018 - 02/2010
2	Leukoencephalopathies 01/2016 - 02/2003
2	Thymoma (Thymic Carcinoma) 08/2014 - 01/2008
2	Atrophy 07/2013 - 01/2004
2	Glioblastoma (Glioblastoma Multiforme) 10/2006 - 05/2003
1	COVID-19 01/2021
1	Optic Neuritis (Retrobulbar Neuritis) 04/2015
1	Persistent Infection 12/2012
1	Vitamin D Deficiency 12/2011
1	Neurodegenerative Diseases (Neurodegenerative Disease) 09/2011
1	Autoimmune Diseases (Autoimmune Disease) 03/2011
1	Herpes Zoster 02/2010
1	Body Weight (Weight, Body) 02/2010
1	Stroke (Strokes) 07/2008
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2006
1	Cardiomyopathies (Cardiomyopathy) 12/2006
1	Pain (Aches) 05/2006
1	Leukopenia 05/2006
1	Glioma (Gliomas) 01/2006
1	Injection Site Reaction 11/2005
1	Chronic Progressive Multiple Sclerosis 05/2005
1	Gastritis 12/2004

Drug/Important Bio-Agent (IBA)

14	Cladribine FDA LinkGeneric 01/2021 - 02/2010
13	TabletsIBA 01/2021 - 02/2010
7	Proteins (Proteins, Gene)FDA Link 01/2016 - 03/2002
6	CytokinesIBA 05/2005 - 06/2002
5	Glatiramer Acetate (Copaxone)FDA Link 10/2021 - 02/2009
4	Interferon beta-1a FDA Link 01/2022 - 01/2004
4	InterferonsIBA 01/2012 - 11/2004
4	Interferon-betaIBA 02/2009 - 11/2004
4	Messenger RNA (mRNA)IBA 09/2004 - 07/2002
3	ChemokinesIBA 11/2005 - 11/2004
2	Pharmaceutical PreparationsIBA 01/2022 - 06/2010
2	Alemtuzumab (Campath)FDA Link 07/2018 - 01/2016
2	siponimodIBA 09/2016 - 08/2013
2	Interleukin-12 (IL 12)IBA 08/2014 - 04/2003
2	ElementsIBA 12/2012 - 02/2005
2	AntigensIBA 12/2012 - 02/2005
2	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2012 - 12/2006
2	Monoclonal AntibodiesIBA 03/2008 - 03/2007
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2004 - 01/2004
2	Indicators and Reagents (Reagents)IBA 01/2004 - 08/2002
2	Ciliary Neurotrophic Factor (CNTF)IBA 06/2002 - 03/2002
1	1- cyclohexyl- 3- (2- (4- morpholinyl)ethyl)carbodiimideIBA 08/2022
1	Cysteine (L-Cysteine)FDA Link 01/2016
1	PlasminogenIBA 01/2016
1	TACI receptor-IgG Fc fragment fusion proteinIBA 04/2015
1	Interferon Type IIBA 08/2014
1	ConnectinIBA 08/2014
1	AutoantibodiesIBA 08/2014
1	Ryanodine Receptor Calcium Release Channel (Ryanodine Receptor)IBA 08/2014
1	Cholinergic ReceptorsIBA 08/2014
1	3' Untranslated Regions (3' UTR)IBA 05/2014
1	MicroRNAs (MicroRNA)IBA 05/2014
1	Therapeutic UsesIBA 08/2013
1	Vitamin D FDA LinkGeneric 12/2011
1	Cholecalciferol (Vitamin D3)FDA Link 12/2011
1	tau Proteins (tau Protein)IBA 09/2011
1	IronIBA 09/2011
1	GadoliniumIBA 09/2011
1	SynucleinsIBA 09/2011
1	TYK2 Kinase (Tyrosine Kinase 2)IBA 03/2011
1	Junctional Adhesion Molecule AIBA 10/2010
1	Imatinib Mesylate (Gleevec)FDA Link 07/2008
1	Mitochondrial DNA (mtDNA)IBA 02/2008
1	Trans-Activators (Trans-Acting Factor)IBA 01/2008
1	HLA Antigens (Human Leukocyte Antigens)IBA 01/2008
1	HLA-DR Antigens (HLA-DR)IBA 01/2008
1	Interferon-gamma (Interferon, gamma)IBA 01/2008
1	StathminIBA 01/2008
1	NucleotidesIBA 01/2008
1	SteroidsIBA 01/2008
1	Biomarkers (Surrogate Marker)IBA 03/2007
1	Immunosuppressive Agents (Immunosuppressants)IBA 03/2007
1	Neutralizing AntibodiesIBA 03/2007
1	NimustineIBA 10/2006
1	Teniposide (VM 26)FDA Link 10/2006
1	Analgesics (Analgesic Drugs)IBA 05/2006
1	cadherin 5IBA 01/2006
1	PercollIBA 01/2006
1	Interferon beta-1b (Betaseron)FDA Link 05/2005
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 05/2005
1	DNA (Deoxyribonucleic Acid)IBA 02/2005
1	Interleukin-8 (Interleukin 8)IBA 12/2004
1	Member 14 Tumor Necrosis Factor ReceptorsIBA 11/2004

Therapy/Procedure

18	Therapeutics 08/2021 - 01/2004
3	Immunotherapy 02/2009 - 12/2006
2	Injections 03/2007 - 11/2005
1	Neurological Rehabilitation 03/2022
1	Treatment Delay 07/2013
1	Subcutaneous Injections 03/2007
1	Immunomodulation 12/2006
1	Radiotherapy 10/2006
1	Drug Therapy (Chemotherapy) 10/2006